Your browser doesn't support javascript.
loading
Oxaliplatin-Fluoropyrimidine Combination (XELOX) Therapy Does Not Affect Plasma Amino Acid Levels and Plasma Markers of Oxidative Stress in Colorectal Cancer Surgery Patients: A Pilot Study.
Aquilani, Roberto; Brugnatelli, Silvia; Dossena, Maurizia; Maestri, Roberto; Delfanti, Sara; Buonocore, Daniela; Boschi, Federica; Simeti, Elena; Condino, Anna Maria; Verri, Manuela.
Afiliação
  • Aquilani R; Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
  • Brugnatelli S; Medical Oncology Division, Fondazione IRCCS, Policlinico San Matteo, 27100 Pavia, Italy.
  • Dossena M; Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
  • Maestri R; Department of Biomedical Engineering of the Montescano Institute, Istituti Clinici Scientifici Maugeri IRCCS, 27040 Montescano (PV), Italy.
  • Delfanti S; Medical Oncology Division, Fondazione IRCCS, Policlinico San Matteo, 27100 Pavia, Italy.
  • Buonocore D; Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
  • Boschi F; Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
  • Simeti E; Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
  • Condino AM; Department of Drug Sciences, University of Pavia, 27100 Pavia, Italy.
  • Verri M; Department of Biology and Biotechnology "Lazzaro Spallanzani", University of Pavia, 27100 Pavia, Italy.
Nutrients ; 11(11)2019 Nov 05.
Article em En | MEDLINE | ID: mdl-31694176
Chemotherapy for colorectal cancer may lower muscle protein synthesis and increase oxidative stress. We hypothesize that chemotherapy may worsen plasma amino acids (AAs) and markers of oxidative stress (MOS). Therefore, this study aimed to document plasma AAs and MOS before, during and after chemotherapy in colorectal cancer (CRC) surgery patients. Fourteen normal-weight CRC patients were enrolled one month after surgery and scheduled for oxaliplatin-fluoropyrimidine combination (XELOX) therapy. Venous blood samples for AA and MOS (malondialdehyde, MDA; 8-hydroxy-2'-deoxyguanosine, 8-OHdG) measurements were drawn in fasting patients before each oxaliplatin infusion at initiation (A), 1 month (B) and 3 months (C) of the therapy, and after XELOX had finished (6 months, D). The results showed that during XELOX therapy (from phase B to phase D), in comparison to baseline (phase A), the branched chain amino acid/essential amino acid ratio, branched chain amino acids expressed as a percentage of total AAs, and arginine expressed as a percentage of total AAs significantly decreased (p = 0.017, p = 0.028, p = 0.028, respectively). Plasma levels of MOS did not change significantly. This study indicates that XELOX therapy does not affect plasma AA levels or worsen oxidative stress.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxaloacetatos / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Estresse Oxidativo / Capecitabina / Aminoácidos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oxaloacetatos / Neoplasias Colorretais / Protocolos de Quimioterapia Combinada Antineoplásica / Estresse Oxidativo / Capecitabina / Aminoácidos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article